Risk for Hepatitis E Virus Transmission by Solvent/Detergent–Treated Plasma
Pierre Gallian
, Sébastien Lhomme, Pascal Morel, Sylvie Gross, Carole Mantovani, Lisette Hauser, Xavier Tinard, Elodie Pouchol, Rachid Djoudi, Azzedine Assal, Florence Abravanel, Jacques Izopet, and Pierre Tiberghien
Author affiliations: Aix-Marseille Université, Marseille, France (P. Gallian); Institut National de la Santé et de la Recherche Médicale, Marseille (P. Gallian); Etablissement Français du Sang, La Plaine, Saint-Denis, France (P. Gallian, P. Morel, S. Gross, E. Pouchol, R. Djoudi, P. Tiberghien); Institut National de la Santé et de la Recherche Médicale, Toulouse, France (S. Lhomme, F. Abravanel, J. Izopet); Hôpital Purpan, Toulouse (S. Lhomme, F. Abravanel, J. Izopet); Etablissement Français du Sang Nouvelle Aquitaine, Bordeaux, France (C. Mantovani, A. Assal); Etablissement Français du Sang Ile-de-France, Ivry sur Seine, France (L. Hauser); Etablissement Français du Sang Grand Est, Nancy, France (X. Tinard); Université de Franche-Comté, Besançon, France (P. Tiberghien)
Main Article
Figure
Figure. Transfused, HEV-infected solvent/detergent–treated plasma and recipient HEV status. A) Lot A; B) lot B. Top values along each x-axis indicate the number of solvent/detergent–treated plasma units transfused per recipient; bottom values indicate HEV viral load (IU/recipient). HEV, hepatitis E virus.
Main Article
Page created: August 28, 2020
Page updated: November 19, 2020
Page reviewed: November 19, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.